LD
Therapeutic Areas
Kodiak Sciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Zenkuda (tarcocimab tedromer) | Wet AMD, Diabetic Retinopathy, Retinal Vein Occlusion | Phase 3 |
| KSI-501 | Wet AMD, Diabetic Macular Edema, Retinal Vein Occlusion, Diabetic Retinopathy | Phase 3 |
| KSI-101 | Macular Edema Secondary to Inflammation (MESI) | Phase 3 |
Leadership Team at Kodiak Sciences
VP
Victor Perlroth
Chairman and Chief Executive Officer
JB
John Borgeson
Chief Financial Officer
DS
Dolly S. Chang
Chief Scientific Officer
AQ
Almas Qudrat
Chief Quality Officer
PV
Pablo Velazquez-Martin
Chief Medical Officer
HL
Hong Liang
SVP, Development
SR
Stephen Raillard
SVP, Chemical Development and Manufacturing